1-4 of 4
Cherie Dunphy, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma

Cassandra L Jacobs, MS, Amee Patel, Dereje Jima, MS, Qingquan Liu, PhD, Adrienne Greenough, Jenny Zhang, Cherie Dunphy, MD, Kristy Richards, PhD, MD, Wai Choi, MBBS, MRCP, Gopesh Srivastava, Wing Y Au, Andrew M Evens, DO, MSc, Leo I Gordon, MD, FACP, Magdalena Czader, David A. Rizzieri, MD, Anand S. Lagoo, MD, PhD, Karen P. Mann, MD, PhD, Christopher R Flowers, MD, MS, Leon Bernal-Mizrachi, MD, Kikkeri Naresh, Micah Luftig, PhD, Amy Chadburn, MD, Eric Hsi, MD, Michael A. Thompson, MD, PhD, Javed Gill, MD, Sandeep Dave, MD
Journal: Blood
Blood (2010) 116 (21): 803.
https://doi.org/10.1182/blood.V116.21.803.803
Published: 2010
Journal Articles

Clinical Impact of TP53 Gene Mutations in Diffuse Large B-Cell Lymphoma (DLBCL): An International DLBCL Rituxan-CHOP Consortium Program Study.

Ken H. Young, MD, PhD, Nancy Patten, PhD, Sim Truong, PhD, Jens Eickhoff, PhD, Gabrielle L. Rocque, MD, Jeffrey T. Malik, MD, Yan Li, PhD, Kazunori Kanehira, MD, PhD, Matthew Twohig, MD, William M. Rehrauer, PhD, Michelle A. Waknitz, MS, Brad S. Kahl, MD, Michael B. Moller, MD, PhD, Alexander Tzankov, PhD, Santiago M. Moreno, MD, Miguel A. Piris, MD, Carlo Visco, MD, Karen Dybkaer, PhD, April Chiu, MD, Attilio Orazi, MD, Jeff C. Chang, MD, PhD, Govind Bhagat, MD, Jane N. Winter, MD, Huan-You Wang, MD, PhD, Cherie Dunphy, MD, Stacey O'Neill, MD, PhD, Eric D. Hsi, MD, Xianfeng Zhao, MD, PhD, Kristin Hunt, MD, Weina Chen, MD, PhD, Ronald S. Go, MD, William W.L. Choi, MD, Fan Zhou, MD, PhD, Magdalena Czader, MD, PhD, Yong Li, PhD, Suzanne Selvaggi, MD, James S. Malter, MD, Lin Wu, PhD
Journal: Blood
Blood (2009) 114 (22): 967.
https://doi.org/10.1182/blood.V114.22.967.967
Published: 2009
Journal Articles

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

Thomas Shea, MD, Jonathan Serody, MD, PhD, Don Gabriel, MD, PhD, Terrance Comeau, MD, Anastasia Ivanova, PhD, Dominic Moore, PhD, Robert Irons, PA, Whitley Julia, BS, Sharf Andrew, RN, Cherie Dunphy, MD, Brecher Mark, MD
Journal: Blood
Blood (2007) 110 (11): 4940.
https://doi.org/10.1182/blood.V110.11.4940.4940
Published: 2007
Journal Articles

High Relapse Rate Following Alemtuzamab Use in Allogeneic Transplants for Myeloid Hematologic Malignancies.

Thomas C. Shea, MD, Jonathan Serody, MD, PhD, Don Gabriel, MD, PhD, Terrance Comeau, MD, Donald Harvey, PharmD, Robert Irons, PA, David Morris, MD, Andrew Sharf, RN, Carol Krasnov, Cherie Dunphy, MD, Nicholas Banderenko, MD, Mark Brecher, MD
Journal: Blood
Blood (2004) 104 (11): 1826.
https://doi.org/10.1182/blood.V104.11.1826.1826
Published: 2004